CTXR insider transaction filings
Citius Pharmaceuticals, Inc. — 18 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-09-23. Screen CTXR transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for CTXR between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Citius Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-09-23 | 4 | Mazur Leonard L — Chief Executive Officer, Director | Disposition to issuer (D): 125,490 (derivative) · Grant/award (A): 125,490 (derivative) · Disposition to issuer (D): 89,388 (derivative) · Grant/award (A): 89,388 (derivative) | EDGAR |
| 2025-08-12 | 4 | HOLUBIAK MYRON Z — Vice Chairman, Director | Disposition to issuer (D): 31,373 (derivative) · Grant/award (A): 31,373 (derivative) · Disposition to issuer (D): 22,344 (derivative) · Grant/award (A): 22,344 (derivative) | EDGAR |
| 2024-11-12 | 4 | Webb Carol — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | Smith Robert Joseph — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | Bartushak Jaime — Chief Financial Officer | Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | Czuczman Myron — Chief Medical Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | Dutia Suren G — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | Holuka Eugene Myron — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | Mazur Leonard L — Chief Executive Officer, Director, 10% owner | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | MCGRATH DENNIS M — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | HOLUBIAK MYRON Z — Vice Chairman, Director | Grant/award (A): 350,000 (derivative) @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2024-09-27 | 4 | Mazur Leonard L — Chief Executive Officer, Director, 10% owner | Disposition to issuer (D): 3,137,255 (derivative) · Grant/award (A): 3,137,255 (derivative) · Disposition to issuer (D): 2,234,700 (derivative) · Grant/award (A): 2,234,700 (derivative) | EDGAR |
| 2024-09-27 | 4 | HOLUBIAK MYRON Z — Vice Chairman, Director | Disposition to issuer (D): 784,314 (derivative) · Grant/award (A): 784,314 (derivative) · Disposition to issuer (D): 558,597 (derivative) · Grant/award (A): 558,597 (derivative) | EDGAR |
| 2024-08-30 | 4 | Holuka Eugene Myron — Director | Option exercise (M): 2,415 @ $0.01 · Tax withholding (F): 48 @ $0.75 · Option exercise (M): 2,415 (derivative) @ $0 | EDGAR |
| 2024-08-30 | 4 | Webb Carol — Director | Option exercise (M): 12,071 @ $0.01 · Tax withholding (F): 236 @ $0.77 · Option exercise (M): 12,071 (derivative) @ $0 | EDGAR |
| 2024-04-05 | 4 | Mazur Leonard L — Chief Executive Officer, Director, 10% owner | Disposition to issuer (D): 1,165,048 (derivative) · Grant/award (A): 1,165,048 (derivative) | EDGAR |
| 2024-04-05 | 4 | HOLUBIAK MYRON Z — Vice Chairman, Director | Disposition to issuer (D): 129,450 (derivative) · Grant/award (A): 129,450 (derivative) | EDGAR |
| 2024-03-18 | 4 | Smith Robert Joseph — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Citius Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-21 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-01 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-29 | 8-K | 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-06 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-03-31 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CTXR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →